 |
|
Human Papillomavirus Testing as a Screening Tool for Cervical Cancer
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In their study of the utility of testing for high-risk human papillomavirus (HPV) in underprivileged women in rural Costa Rica, Dr Schiffman and colleagues1 suggested that in women older than 35 years, this test is comparable or even superior to the Papanicolaou (Pap) test. The concept of HPV infection as an important factor in the genesis of cancer of the uterine cervix is based on the observation that the DNA of "high risk" viruses is commonly found in nearly all invasive cancers and that viral proteins may impede events in the normal cell cycle.2 The initial theory that the mere presence of high-risk HPV is tantamount to a precancerous or malignant lesion of the uterine cervix is no longer tenable today because of very high rates of transient infections observed in sexually active young women.3 Thus, HPV testing in women aged 18 to 35 years, the age . . . [Full Text of this Article]
RELATED ARTICLE
HPV DNA Testing in Cervical Cancer Screening: Results From Women in a High-Risk Province of Costa Rica
Mark Schiffman, Rolando Herrero, Allan Hildesheim, Mark E. Sherman, Maria Bratti, Sholom Wacholder, Mario Alfaro, Martha Hutchinson, Jorge Morales, Mitchell D. Greenberg, and Attila T. Lorincz
JAMA. 2000;283(1):87-93.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)
Kulasingam et al.
JNCI J Natl Cancer Inst 2006;98:92-100.
ABSTRACT
| FULL TEXT
Policy Analysis of Cervical Cancer Screening Strategies in Low-Resource Settings: Clinical Benefits and Cost-effectiveness
Goldie et al.
JAMA 2001;285:3107-3115.
ABSTRACT
| FULL TEXT
|
